286 related articles for article (PubMed ID: 34623891)
1. Disparities in Treatment with Direct-Acting Hepatitis C Virus Antivirals Persist Among Adults Coinfected with HIV and Hepatitis C Virus in US Clinics, 2010-2018.
Simoncini GM; Hou Q; Carlson K; Buchacz K; Tedaldi E; Palella F; Durham M; Li J;
AIDS Patient Care STDS; 2021 Oct; 35(10):392-400. PubMed ID: 34623891
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C treatment uptake and response among human immunodeficiency virus/hepatitis C virus-coinfected patients in a large integrated healthcare system.
Lam JO; Hurley LB; Chamberland S; Champsi JH; Gittleman LC; Korn DG; Lai JB; Quesenberry CP; Ready J; Saxena V; Seo SI; Witt DJ; Silverberg MJ; Marcus JL
Int J STD AIDS; 2019 Jun; 30(7):689-695. PubMed ID: 31046611
[TBL] [Abstract][Full Text] [Related]
3. Barriers to hepatitis C direct-acting antiviral therapy among HIV/hepatitis C virus-coinfected persons.
Jatt LP; Gandhi MM; Guo R; Sukhija-Cohen A; Bhattacharya D; Tseng CH; Chew KW
J Gastroenterol Hepatol; 2021 Apr; 36(4):1095-1102. PubMed ID: 32840904
[TBL] [Abstract][Full Text] [Related]
4. Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower Risk of Hepatocellular Carcinoma After Sustained Virological Response to Direct-acting Antivirals in Hepatitis C Infected Patients With Advanced Fibrosis.
Corma-Gómez A; Macías J; Lacalle-Remigio JR; Téllez F; Morano L; Rivero A; Serrano M; Ríos MJ; Vera-Méndez FJ; Alados JC; Real LM; Palacios R; Santos IL; Imatz A; Pineda JA;
Clin Infect Dis; 2021 Oct; 73(7):e2109-e2116. PubMed ID: 32766891
[TBL] [Abstract][Full Text] [Related]
5. Sustained virological response after treatment with direct antiviral agents in individuals with HIV and hepatitis C co-infection.
Lodi S; Klein M; Rauch A; Epstein R; Wittkop L; Logan R; Rentsch CT; Justice AC; Touloumi G; Berenguer J; Jarrin I; Egger M; Puoti M; D'Arminio Monforte A; Gill J; Salmon Ceron D; van Sighem A; Linas B; van der Valk M; Hernán MA;
J Int AIDS Soc; 2022 Dec; 25(12):e26048. PubMed ID: 36562643
[TBL] [Abstract][Full Text] [Related]
6. Predictive factors of hepatitis C virus eradication after interferon-free therapy in HIV coinfection.
Domínguez-Domínguez L; Bisbal O; Matarranz M; Lagarde M; Pinar Ó; Hernando A; Lumbreras C; Rubio R; Pulido F
Eur J Clin Microbiol Infect Dis; 2019 Apr; 38(4):725-734. PubMed ID: 30687869
[TBL] [Abstract][Full Text] [Related]
7. Impact of Hepatitis C Virus Cure on Depressive Symptoms in the Human Immunodeficiency Virus-Hepatitis C Virus Coinfected Population in Canada.
Marathe G; Moodie EEM; Brouillette MJ; Lanièce Delaunay C; Cox J; Martel-Laferrière V; Gill J; Cooper C; Pick N; Vachon ML; Walmsley S; Klein MB;
Clin Infect Dis; 2023 Feb; 76(3):e702-e709. PubMed ID: 35789253
[TBL] [Abstract][Full Text] [Related]
8. Hepatitis C and human immunodeficiency virus coinfection in the era of direct-acting antiviral agents: No longer a difficult-to-treat population.
Sikavi C; Chen PH; Lee AD; Saab EG; Choi G; Saab S
Hepatology; 2018 Mar; 67(3):847-857. PubMed ID: 29108121
[TBL] [Abstract][Full Text] [Related]
9. Risk of severe clinical events after sustained virological response following direct-acting antiviral therapy in HIV and hepatitis C virus coinfected participants.
Chalouni M; Wittkop L; Bani-Sadr F; Lacombe K; Esterle L; Gilbert C; Miailhes P; Zucman D; Valantin MA; Brégigeon-Ronot S; Morlat P; Billaud E; Piroth L; Naqvi A; Sogni P; Salmon D;
HIV Med; 2021 Oct; 22(9):791-804. PubMed ID: 34212476
[TBL] [Abstract][Full Text] [Related]
10. Impact of CD4+ blood cell count and HIV viral load on treatment response with direct acting antivirals in HIV and HCV coinfected patients: insights from the German Hepatitis C-Registry.
Bischoff J; Mauss S; Cordes C; Lutz T; Scholten S; Cornberg M; Manns MP; Baumgarten A; Rockstroh JK
HIV Clin Trials; 2018 Dec; 19(6):225-234. PubMed ID: 30890063
[TBL] [Abstract][Full Text] [Related]
11. Clinical Characteristics and Treatment Outcomes of Patients with Hepatitis C Virus and Human Immunodeficiency Virus Coinfection: Experience at a Single Center in Korea.
Lim DH; Jeong JY; Nam S; Choi J; Kwon HC; Yoon YB; Kim Y; Chin B
J Korean Med Sci; 2021 Nov; 36(46):e308. PubMed ID: 34845874
[TBL] [Abstract][Full Text] [Related]
12. Liver Fibrosis in Human Immunodeficiency Virus (HIV)-Hepatitis C Virus (HCV) Coinfection Before and After Sustained Virologic Response: What Is the Best Noninvasive Marker for Monitoring Regression?
Kronfli N; Young J; Wang S; Cox J; Walmsley S; Hull M; Cooper C; Martel-Laferriere V; Wong A; Pick N; Klein MB;
Clin Infect Dis; 2021 Aug; 73(3):468-477. PubMed ID: 32504083
[TBL] [Abstract][Full Text] [Related]
13. Increased mortality in HIV/HCV-coinfected compared to HCV-monoinfected patients in the DAA era due to non-liver-related death.
Chalouni M; Pol S; Sogni P; Fontaine H; Lacombe K; Marc-Lacombe J; Esterle L; Dorival C; Bourlière M; Bani-Sadr F; de Ledinghen V; Zucman D; Larrey D; Salmon D; Carrat F; Wittkop L;
J Hepatol; 2021 Jan; 74(1):37-47. PubMed ID: 32798585
[TBL] [Abstract][Full Text] [Related]
14. Liver Stiffness-Based Strategies Predict Absence of Variceal Bleeding in Cirrhotic Hepatitis C Virus-Infected Patients With and Without Human Immunodeficiency Virus Coinfection After Sustained Virological Response.
Corma-Gómez A; Macías J; Morano L; Rivero A; Téllez F; Ríos MJ; Santos M; Serrano M; Palacios R; Merino D; Real LM; De Los Santos I; Vera-Méndez FJ; Galindo MJ; Pineda JA;
Clin Infect Dis; 2021 Mar; 72(5):e96-e102. PubMed ID: 33211801
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfected Individuals: Results From a Pan-European Study.
Amele S; Peters L; Rodger A; Lundgren J; Rockstroh J; Matulionyte R; Leen C; Jabłonowska E; Østergaard L; Bhagani S; Sarcletti M; Clarke A; Falconer K; Wandeler G; Domingo P; Maltez F; Zaccarelli M; Chkhartisvili N; Szlavik J; Stephan C; Fonquernie L; Aho I; Mocroft A;
J Acquir Immune Defic Syndr; 2021 Feb; 86(2):248-257. PubMed ID: 33079903
[TBL] [Abstract][Full Text] [Related]
16. Direct, indirect and total effect of HIV coinfection on the risk of non-liver-related cancer in hepatitis C virus-infected patients treated by direct-acting antivirals: a mediation analysis.
Chalouni M; Pol S; Sogni P; Fontaine H; Lacombe K; Lacombe JM; Esterle L; Dorival C; Bourlière M; Bani-Sadr F; de Ledinghen V; Zucman D; Larrey D; Salmon D; Carrat F; Wittkop L; ; Martinez V
HIV Med; 2021 Nov; 22(10):924-935. PubMed ID: 34402547
[TBL] [Abstract][Full Text] [Related]
17. Low Utilization of Direct-Acting Antiviral Agents in a Large National Cohort of HIV and HCV Coinfected Medicare Patients in the United States: Implications for HCV Elimination.
Du P; Jung J; Kalidindi Y; Farrow K; Riley T; Whitener C
J Public Health Manag Pract; 2022 Mar-Apr 01; 28(2):130-134. PubMed ID: 32011599
[TBL] [Abstract][Full Text] [Related]
18. The risk of hepatitis C virus recurrence in hepatitis C virus-infected patients treated with direct-acting antivirals after achieving a sustained virological response: A comprehensive analysis.
Huang P; Wang Y; Yue M; Ge Z; Xia X; Jeyarajan AJ; Holmes JA; Yu R; Zhu C; Yang S; Lin W; Chung RT
Liver Int; 2021 Oct; 41(10):2341-2357. PubMed ID: 34051040
[TBL] [Abstract][Full Text] [Related]
19. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy.
Milazzo L; Lai A; Calvi E; Ronzi P; Micheli V; Binda F; Ridolfo AL; Gervasoni C; Galli M; Antinori S; Sollima S
HIV Med; 2017 Apr; 18(4):284-291. PubMed ID: 27477612
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, Tolerability, and Compliance of Direct Acting Antivirals in Patients with HIV and Hepatitis C Coinfection: A Real-Life Experience.
Mishra S; Taneja S; De A; Verma N; Premkumar M; Naidu GSRSNK; Sharma A; Duseja A; Dhiman RK; Singh V
AIDS Res Hum Retroviruses; 2023 Sep; 39(9):453-458. PubMed ID: 36511384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
